PARP1 and chronic myelogenous leukemia, BCR-ABL1 positive: Preclinical studies have shown sensitivity to inhibition of PARP1 and DNA ligase IIIα inhibition in CML cells, given their role in the alternate NHEJ pathway [6,77,78].